Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


To futility but not beyond as Infinity's Hedgehog becomes road kill

This article was originally published in Scrip

Executive Summary

Infinity Pharmaceuticals said it was halting another Phase II trial of its lead candidate, saridegib (also known as IPI-926), a Hedgehog pathway inhibitor, in patients with locally advanced, inoperable chondrosarcoma, a rare and life-threatening cancer of the cartilage. Independent monitors determined that the experimental drug was performing no better than placebo in the disease. The company is also halting an exploratory study of the drug after a disappointing look at the results for the first 12 evaluable patients with myelofibrosis, an incurable malignancy of the bone marrow.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts